Clinical trial
An Open-label, Multicenter Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLF4113 for Injection in Participants With Metastatic Prostate Cancer.
NCT07636707 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multicenter Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of QLF4113 for Injection in Participants With Metastatic Prostate Cancer.
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- July 20, 2026
- Completion date
- December 5, 2028
- Enrollment
- 140 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer